Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 29 of 33 · 1559 articles
People with Crohn’s disease can have liver involvement that may be missed on routine exams. Quantitative liver MRI measures (fat fraction and extracellular volume) could help detect and monitor subtle liver injury...
If validated, the study points to a specific neutrophil subset that may drive inflammation and barrier damage in IBD, and to CXCR4 as a possible therapeutic target. That could open new biology-based treatment approaches...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and...
Cure8 found this source from Endokrynologia Polska, but the page could not be read reliably yet. It is tagged for Crohn's disease, Abdominal Pain, and Tests and monitoring. Open the original article for the full details.
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
Endometriosis involving the intestine can mimic Crohn’s disease symptoms and lead to misdiagnosis or delayed correct treatment. Patients with IBD-like symptoms who are of reproductive age may need evaluation for bowel...
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.
Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...
Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.
Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from European radiology.
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic...
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...
This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....
The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...
A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...
Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
This study shows that patients' comfort partly explains how clinical disease activity affects quality of life in ulcerative colitis, suggesting comfort-focused nursing care could help patients feel better even when...
Colorectal lymphoma in children can mimic IBD flares or cause surgical emergencies; recognizing this can prevent inappropriate escalation of immunosuppression and speed correct diagnosis and treatment.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
Malnutrition is common in Crohn’s disease and more likely during active disease; recognizing it matters because nutritional status affects symptoms, recovery, and treatment tolerance.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
